Siga(SIGA)
NEW YORK, NYBiotechnology
Focus: Siga is a public biotechnology company focused on small-molecule antivirals for infectious diseases, with a market-leading position in orthopoxvirus treatment through its flagship product TPOXX (tecovirimat). The company generates meaningful revenue from government stockpiling and commercial demand for mpox and smallpox countermeasures.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Siga
AI assessmentNot HiringNo open roles listed right now. Follow Siga to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$140M
Key Products
Peak5.3yr
Sole approved antiviral for orthopoxviruses with dual LOE dates (2031–2032); drives >80% of company revenue through government contracts and commercial demand.
Help build intelligence for Siga
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.